openPR Logo
Press release

Investigation announced for Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) shares

09-21-2021 06:31 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Ocugen, Inc. (NASDAQ: OCGN) shares.

An investigation on behalf of current long term investors in Ocugen, Inc. (NASDAQ: OCGN) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Ocugen, Inc.

Investors who are current long term investors in Ocugen, Inc. (NASDAQ: OCGN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: OCGN stocks follows a lawsuit filed against Ocugen, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: OCGN stocks, concerns whether certain Ocugen directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges that Ocugen, Inc made materially false and/or misleading statements and/or failed to disclose that the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), that Ocugen, Inc would not file an EUA with the FDA, and that as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Those who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and should contact the Shareholders Foundation. Contact: Shareholders Foundation, Inc.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) shares here

News-ID: 2401411 • Views:

More Releases from Shareholders Foundation

Investigation announced for Investors in GrafTech International Ltd. (NYSE: EAF) over potential Wrongdoing
Investigation announced for Investors in GrafTech International Ltd. (NYSE: EAF) …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of GrafTech International Ltd. Investors who are current long term investors in GrafTech International Ltd. (NYSE: EAF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: EAF stocks follows a lawsuit filed against GrafTech International
Lawsuit filed for Long-Term Investors of Amplitude, Inc. (NASDAQ: AMPL) against certain Directors of Amplitude, Inc.
Lawsuit filed for Long-Term Investors of Amplitude, Inc. (NASDAQ: AMPL) against …
A long-term investor in shares of Amplitude, Inc. (NASDAQ: AMPL) filed a lawsuit against certain directors of Amplitude, Inc. over alleged breaches of fiduciary duties. Investors who are current long term investors in Amplitude, Inc. (NASDAQ: AMPL) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The plaintiff alleges certain current and former insiders of Amplitude, Inc. profited from misrepresentations they made about
Investigation announced for Investors who lost money with shares of GameStop Corp. (NYSE: GME)
Investigation announced for Investors who lost money with shares of GameStop Cor …
An investigation was announced for investors of GameStop Corp. (NYSE: GME) shares over potential securities laws violations by GameStop Corp. Investors who purchased shares of GameStop Corp. (NYSE: GME), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether certain statements by GameStop Corp. regarding its business, its prospects and its operations were materially false and
Investigation announced for Long-Term Investors in shares of Brooge Energy Limited (NASDAQ: BROG) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of Brooge Energy Limit …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Brooge Energy Limited. Investors who are current long term investors in Brooge Energy Limited (NASDAQ: BROG) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: BROG stocks follows a lawsuit filed against Brooge

All 5 Releases


More Releases for Ocugen

Lawsuit filed for Investors in shares of Ocugen, Inc. (NASDAQ: OCGN)
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit over alleged violations of Federal Securities Laws by Ocugen, Inc. Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: August 17, 2021. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Malvern, PA based Ocugen, Inc., a clinical-stage
Retinitis Pigmentosa (RP) Market 2025 : Ocugen, Inc., ReGenX Biosciences, LLC, S …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells. Proportions of retinal capacity, for example, the electroretinogram, demonstrate that photoreceptor capacity is decreased normally quite before symptomic night visual impairment, visual-field scotomas, or diminished visual sharpness
Retinitis Pigmentosa (RP) Market | Ocugen, Inc., ReGenX Biosciences, LLC, Sucamp …
Global Retinitis Pigmentosa (RP) Market: Overview Retinitis Pigmentosa (RP), an inherited retinal condition causing retinal degeneration and visual field loss, is a rare disease. Its initial symptoms are reduced night vision and loss of peripheral vision. It gradually causes blindness. There is no definitive cure for retinitis pigmentosa. Therefore, the market for treating this genetic disorder is vastly untapped. The available therapies apply various approaches such as stem cell therapy and
Retinitis Pigmentosa (RP) Market | Amarantus BioScience Holdings, Inc., Ocugen, …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise. Get Sample Copy of
Retinitis Pigmentosa (RP) Market | Amarantus BioScience Holdings, Inc., Ocugen, …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise. Get Brochure of the
Choroidal Neovascularization Therapeutics Pipeline Analysis 2018 | Graybug Visio …
Choroidal neovascularization is a type of medical condition in which new blood vessels are formed from choroid and extend into the subretinal space, or subretinal pigment epithelium, or a combination of both. Download the sample report @ https://www.pharmaproff.com/request-sample/1122 The disease can be symptomatized by a painless loss of vision, paracentral or central scotoma, and metamorphopsia. Choroidal neovascularization can be diagnosed by indocyanine green angiography, spectral domain optical coherence tomography, and fluorescein angiography.